J. Raynaud

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

J. Blay, R. Schilsky, S. Ikeda, 2022, JCO precision oncology.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

J Jack Lee, Eitan Rubin, Razelle Kurzrock, 2019, Nature Medicine.

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

J. Blay, R. Schilsky, S. Ikeda, 2022, Therapeutic advances in medical oncology.

Equal access to innovative therapies and precision cancer care

J. Blay, G. Vassal, D. Pérol, 2016, Nature Reviews Clinical Oncology.

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

N. Girard, R. Schilsky, J. Lee, 2022, Cancer Medicine.

Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

N. Girard, J. Lee, B. Leyland-Jones, 2019, Annals of Oncology.

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival

N. Girard, R. Schilsky, R. Berger, 2021, npj Precision Oncology.

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

R. Schilsky, E. Felip, M. Ducreux, 2023, Therapeutic advances in medical oncology.